- Conditions
- Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture
- Interventions
- Romosozumab, Placebo, Zoledronic acid, Calcium and Vitamin D
- Drug · Dietary Supplement
- Lead sponsor
- Susan L. Greenspan
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 156
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sarcopenia, Osteoporosis
- Interventions
- Denosumab, Zoledronic Acid, Denosumab Placebo, Zoledronic Acid Placebo
- Drug · Other
- Lead sponsor
- Nami Safai Haeri
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV
- Interventions
- setrusumab, Calcium, Vitamin D, zoledronic acid (optional)
- Drug · Dietary Supplement
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Jacksonville, Florida • Baltimore, Maryland + 9 more
- Conditions
- Osteoporosis
- Interventions
- Zoledronic acid, Placebo, Teriparatide
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 45 Years to 89 Years · Female only
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- assessment of therapy complications
- Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Up to 120 Years
- Enrollment
- 3,571 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 451
- States / cities
- Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more
- Conditions
- Prostate Cancer
- Interventions
- zoledronate therapy, PET Scan
- Drug · Device
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Farmington Hills, Michigan
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Zoledronic Acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 127 participants
- Timeline
- 2004 – 2007
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Wilmington, Delaware • Boise, Idaho + 7 more
- Conditions
- Osteoporosis
- Interventions
- FES-Rowing, Zoledronic acid
- Other · Drug
- Lead sponsor
- Antonio Lazzari
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Charlestown, Massachusetts
- Conditions
- HIV Infections, Osteopenia, Osteoporosis
- Interventions
- Zoledronate, Zoledronate placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Kidney Cancer
- Interventions
- IL2, Zoledronic acid
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Giant Cell Tumor of Bone
- Interventions
- Zoledronic Acid
- Drug
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2028
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 9 more
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm, Pain
- Interventions
- Pamidronate, Zoledronic acid, Sm 153 lexidronam
- Drug · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Osteoporosis
- Interventions
- DMAB Discontinuation and Switching
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
- Interventions
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy, Zoledronic Acid
- Drug · Other · Radiation
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Bariatric Surgery Candidate, Bone Loss
- Interventions
- Denosumab, Placebo, Zoledronic Acid
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- San Francisco, California • Boston, Massachusetts
- Conditions
- Osseous Lesions From Metastatic Breast Cancer
- Interventions
- Zometa™
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 110 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Paget's Disease of the Bone, Hypocalcemia
- Interventions
- Reclast (ZOL446, zoledronic acid), Calcium, Vitamin D
- Drug · Dietary Supplement
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Gainesville, Georgia + 6 more
- Conditions
- Prostate Cancer
- Interventions
- zoledronic acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
- Interventions
- Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase)
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 79
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 67 more
- Conditions
- Non-Hodgkin's Lymphoma, Lymphoma
- Interventions
- Zoledronic Acid, Vitamin D, Calcium Carbonate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neuroblastoma
- Interventions
- Zoledronic Acid, Aldesleukin
- Drug · Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
- Interventions
- Romosozumab Prefilled Syringe, Placebo, Zoledronic acid 5 mg
- Drug
- Lead sponsor
- Karen Klahr Miller, MD
- Other
- Eligibility
- 20 Years to 60 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Bariatric Surgery Candidate
- Interventions
- Zoledronic Acid, Calcium citrate + vitamin D, Vitamin D3
- Drug · Dietary Supplement
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 25 Years to 100 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- FHA (Functional Hypothalamic Amenorrhea)
- Interventions
- Romosozumab, Placebo, Zoledronic acid
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 30 Years · Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Charlottesville, Virginia